Stay updated with breaking news from Ophthalmol Vis Sci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and ...
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06, 2024 Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found...
Showed visual function and quality-of-life benefits in patients with extrafoveal lesionsSlowed the loss of retinal pigmented epithelial and photoreceptor...
Pregnancy, baby, toddler advice for Canadian parents
Age-related macular degeneration is an increasingly important public health issue due to ageing populations and increased longevity. Age-related macular degeneration affects individuals older than 55 years and threatens high-acuity central vision required for important tasks such as reading, driving, and recognising faces. Advances in retinal imaging have identified biomarkers of progression to late age-related macular degeneration. New treatments for neovascular age-related macular degeneration offer potentially longer-lasting effects, and progress is being made towards a treatment for atroph...